Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07658079

The Effect of the Distance of the Percutaneous Endoscopic Gastrostomy (PEG) Feeding Tube From the Pylorus on Postoperative Outcomes

Nutrition is the intake of essential nutrients in sufficient quantities and at the appropriate times to maintain and improve health and enhance quality of life.

Enteral nutrition is superior to parenteral nutrition and should be preferred. Patients should begin enteral nutrition as soon as possible to protect the gastrointestinal mucosa and maintain normal flora. In patients unable to take food orally, enteral nutrition is provided via a nasogastric/nasojejunal tube or gastrostomy tube.

Gastrostomy is the first choice for patients with a functional gastrointestinal system, poor oral intake, and requiring long-term nutritional support. Feeding tubes can be placed percutaneously or surgically. Percutaneous endoscopic gastrostomy (PEG) is a minimally invasive procedure that does not increase morbidity or mortality compared to surgical gastrostomy, and is cheaper and more time-saving. It was first applied in 1980 as an alternative to surgical gastrostomy. Initially described, a line was drawn between the umblicus and the middle of the left lower costal margin, and a feeding tube was inserted under local anesthesia at the junction of the middle 2/3 and the outer 1/3, with feeding starting the next day. Vudayagiri et al. reported that the placement site is generally 2 cm medial to the costal margin and 2 cm below the xiphoid process.

Different methods for placing a PEG tube into the stomach (pull technique, push technique, and Russell method) are described in the literature, with the most common being the "pull" technique. The 2005 ESPEN guidelines note that in the "pull" technique, gastroscopic visualization of the anterior gastric wall is performed, followed by determination of the puncture site at the distal corpus level.

The exact placement of the PEG feeding tube, both on the skin and within the gastric lumen, is not fully understood. Its localization on the abdominal skin will be optimally determined by endoscopic transillumination. However, its level within the gastric lumen is predictable.

In our study, we aimed to measure the distance of the feeding tube from the pylorus in patients undergoing PEG surgery, to investigate how this affects post-procedure outcomes, and to determine the optimal level within the gastric lumen. Additionally, the catheter placement on the skin will be recorded for each patient. The anatomical skin localization obtained by examining the data of all patients will be defined as the 'Triangle of Çaykara'.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Over 18 years of age
  • No history of major abdominal surgery (appendectomy, hernia, etc.)
  • Patients who started feeding 24 hours after the PEG procedure
  • Patients not using prokinetic agents.

Exclusion criteria

  • History of stomach, small intestine, large intestine surgery or any history of major abdominal surgery
  • Having undergone surgical gastrostomy
  • Expected gastroparesis (hemodynamic instability, inotropic support, electrolyte imbalance, etc.)
  • Intestinal motility disorder
  • Patients who started feeding early

Treatment and study plan

Percutaneous endoscopic gastrostomy

Procedure

The exact placement of the PEG feeding tube, both on the skin and within the gastric lumen, is not fully understood. In this study, researchers aimed to measure the distance of the feeding tube from the pylorus in patients undergoing PEG surgery, investigate how this affects post-procedure outcomes, and determine the optimal level within the gastric lumen. Additionally, the catheter placement on the skin will be recorded for each patient. The anatomical skin localization obtained by analyzing data from all patients will be defined as the 'Çaykara Triangle'.

Primary outcomes

  1. Surgery-related complications

    Time frame: From the procedure through the first 2 weeks

    Incidence of procedure-related and early post-procedure complications

Secondary outcomes

  1. Feeding tolerance

    Time frame: Daily monitoring starting 24 hours after the procedure and continuing for the first 2 weeks.

    Intolerance to enteral nutrition is typically defined by gastrointestinal symptoms such as vomiting, excessive gastric residual volumes (typically >500 mL over 6 hours), abdominal distension, diarrhea, or constipation. All these parameters will be recorded, but particular attention will be paid to measuring excessive volumes of gastric residue.

Other outcomes

  1. Tube-to-pylorus distance (cm)

    Time frame: At the time of the procedure

    This is achieved by advancing a marked catheter through the PEG tube immediately after insertion, and simultaneously performing endoscopy. The distance to the pylorus is measured in centimeters.

  2. PEG tube placement site on the skin

    Time frame: At the time of the procedure

    Determining PEG localization on the anterior abdominal wall using the xiphoid process, umbilicus, and costal margin as reference points.

    The anatomical skin localization obtained by examining the data of all patients will be defined as the 'Triangle of Çaykara'.

Sponsors and collaborators

Lead sponsor

Sisli Hamidiye Etfal Training and Research Hospital

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jun 18, 2026
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.